AQUESTIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Aquestive Therapeutics, Inc. on Behalf of Aquestive Stockholders and Encourages Investors to Contact the Firm
StockNews.AI • 17 hours
High Materiality8/10
Information
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aquestive (AQST) To Contact Him Directly To Discuss Their Options If you purchased or acquired Aquestive
Original sourceAI Summary
Bragar Eagel & Squire is investigating Aquestive Therapeutics for potential securities law violations following an FDA notice revealing deficiencies in the company's NDA for Anaphylm. This investigation could lead to significant legal challenges for AQST, potentially impacting its stock performance and investor sentiment in the near term.
Sentiment Rationale
The stock price has already reacted negatively to the FDA notice. Historical cases show that similar situations often lead to sustained losses until clarity is achieved.
Trading Thesis
Given the FDA notice and ongoing legal investigations, AQST's stock is likely to face downward pressure in the immediate term.
Market-Moving
- FDA's notice on AQST's NDA deficiencies triggered a stock price drop.
- Ongoing legal investigations may deter investor confidence in AQST.
- Possible increased selling pressure from affected shareholders is expected.
- Legal outcomes could alter AQST's long-term business viability.
Key Facts
- Bragar Eagel & Squire is investigating claims against AQST.
- Concerns are related to securities laws and business practices.
- AQST's stock price dropped after FDA notified deficiencies in its NDA.
- Investors encouraged to discuss potential claims with the law firm.
- Legal investigations may impact AQST's stock performance.
Companies Mentioned
- Aquestive Therapeutics (AQST): Investigations may damage AQST's reputation and investor relations.
- Bragar Eagel & Squire, P.C. (N/A): The law firm is spearheading investigations that could pressure AQST's stock.
Legal
This falls under 'Legal' as it involves investigations regarding potential violations of federal securities laws. Legal challenges can significantly affect investor confidence and stock valuation.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aquestive (AQST) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Aquestive stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) --
What's Happening:
- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ:AQST) on behalf of Aquestive stockholders. Our investigation concerns whether Aquestive has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
- On January 9, 2026, Aquestive disclosed that it received a notice from the FDA that it "had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate, Anaphylm™ (epinephrine) Sublingual Film, for the treatment of severe allergic reactions, including anaphylaxis, that preclude discussion of labeling and post-marketing commitments for Anaphylm." Following this news, the price of the Company's stock dropped.
Next Steps:
- If you purchased or otherwise acquired Aquestive shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,
derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
